Nuformix Company Description

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.

It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.

It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

Nuformix plc

Country	United Kingdom
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	3

Contact Details

Address: 60 Gracechurch Street London, EC3V 0HR United Kingdom
Phone	44 12 2362 7222
Website	nuformix.com

Stock Details

Ticker Symbol	NFX
Exchange	London Stock Exchange
Fiscal Year	October - September
Reporting Currency	GBP
ISIN Number	GB00BYW79Y38
SIC Code	2834

Key Executives

Name	Position
Dr. Daniel John Gooding	Executive Director
Dr. Joanne M. Holland	Consultant
Benjamin Harber	Company Secretary